{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:35:06Z","timestamp":1791081306091,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["U19AG032438"],"award-info":[{"award-number":["U19AG032438"]}]},{"name":"NIH","award":["R01AG052550-01A1"],"award-info":[{"award-number":["R01AG052550-01A1"]}]},{"name":"NIH","award":["U01AG042791"],"award-info":[{"award-number":["U01AG042791"]}]},{"name":"NIH","award":["U01AG042791-S1"],"award-info":[{"award-number":["U01AG042791-S1"]}]},{"name":"NIH","award":["R01AG046179"],"award-info":[{"award-number":["R01AG046179"]}]},{"name":"NIH","award":["R01AG53267-S1"],"award-info":[{"award-number":["R01AG53267-S1"]}]},{"name":"NIH","award":["P30NS098577"],"award-info":[{"award-number":["P30NS098577"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00259-023-06209-0","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T09:58:38Z","timestamp":1680688718000},"page":"2669-2682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2\/3 clinical trial of anti-amyloid-\u03b2 monoclonal antibodies in dominantly inherited Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"50","author":[{"given":"Charles D.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Joseph-Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaney","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ","family":"Hornbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Goate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Klunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Joy","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik D.","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Brosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Surti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne Z.","family":"Jim\u00e9nez-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Clarnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Sanchez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ixavier","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Tunali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Masellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Hsiung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Supnet-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammie L. S.","family":"Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DIAN-TU Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"6209_CR1","doi-asserted-by":"publisher","unstructured":"Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. Dominantly inherited alzheimer network\u2013trials unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021;27(7):1187\u201396. https:\/\/doi.org\/10.1038\/s41591-021-01369-8.","DOI":"10.1038\/s41591-021-01369-8"},{"key":"6209_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu E, Schmidt ME, Margolin R, et al. Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692\u2013700.","journal-title":"Neurology"},{"key":"6209_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","volume":"3","author":"JW Landen","year":"2017","unstructured":"Landen JW, Andreasen N, Cronenberger CL, et al. Ponezumab in mild-to-moderate Alzheimer\u2019s disease: randomized phase II PET-PIB study. Alzheimers Dement (N Y). 2017;3:393\u2013401.","journal-title":"Alzheimers Dement (N Y)"},{"key":"6209_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"6209_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"6209_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimer\u2019s Res Ther. 2019;11:101.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"6209_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alz Res Ther. 2021;13:80.","journal-title":"Alz Res Ther"},{"key":"6209_CR8","doi-asserted-by":"publisher","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378(4):321\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1705971.","DOI":"10.1056\/NEJMoa1705971"},{"key":"6209_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","volume":"83","author":"DA Wolk","year":"2012","unstructured":"Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer\u2019s disease: comparison of Florbetapir and Pittsburgh Compound-B PET. J Neurol Neurosurg Psychiatry. 2012;83:923\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6209_CR10","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/brain\/awt142","volume":"136","author":"R Ni","year":"2013","unstructured":"Ni R, Gillberg P-G, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer\u2019s disease brain tissue. Brain. 2013;136:2217\u201327.","journal-title":"Brain"},{"key":"6209_CR11","first-page":"180","volume":"11","author":"Y Su","year":"2019","unstructured":"Su Y, Flores S, Wang G, et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer\u2019s Dement Diagn Assess Dis Monit. 2019;11:180.","journal-title":"Alzheimer\u2019s Dement Diagn Assess Dis Monit"},{"key":"6209_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398\u2013407.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6209_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00259-011-1745-9","volume":"38","author":"BA Thomas","year":"2011","unstructured":"Thomas BA, Erlandsson K, Modat M, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2011;38:1104\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6209_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315 (e1-4).","journal-title":"Alzheimers Dement"},{"key":"6209_CR15","doi-asserted-by":"publisher","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","volume":"110","author":"TLS Benzinger","year":"2013","unstructured":"Benzinger TLS, Blazey T, Jack CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2013;110:E4502-4509.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6209_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4155\/cli.12.93","volume":"2","author":"JC Morris","year":"2012","unstructured":"Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012;2:975\u201384.","journal-title":"Clin Investig (Lond)"},{"key":"6209_CR17","unstructured":"McKay NS, Gordon BA, Hornbeck RC, et al. Neuroimaging within the Dominantly Inherited Alzheimer\u2019s Network (DIAN): PET and MRI. March 2022:2022.03.25.485799."},{"key":"6209_CR18","doi-asserted-by":"publisher","first-page":"e73377","DOI":"10.1371\/journal.pone.0073377","volume":"8","author":"Y Su","year":"2013","unstructured":"Su Y, D\u2019Angelo GM, Vlassenko AG, et al. Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE. 2013;8:e73377.","journal-title":"PLoS ONE"},{"key":"6209_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroimage.2014.11.058","volume":"107","author":"Y Su","year":"2015","unstructured":"Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55\u201364.","journal-title":"Neuroimage"},{"key":"6209_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. NeuroImage. 2012;62:774\u201381.","journal-title":"NeuroImage"},{"key":"6209_CR21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"6209_CR22","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"key":"6209_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.brainres.2016.11.011","volume":"1655","author":"V Tentolouris-Piperas","year":"2017","unstructured":"Tentolouris-Piperas V, Ryan NS, Thomas DL, Kinnunen KM. Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer\u2019s disease. Brain Res. 2017;1655:23\u201332.","journal-title":"Brain Res"},{"key":"6209_CR24","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174\u201384.","journal-title":"J Neurosci"},{"key":"6209_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-021-02342-y","volume":"142","author":"CD Chen","year":"2021","unstructured":"Chen CD, Joseph-Mathurin N, Sinha N, et al. Comparing amyloid-\u03b2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathol. 2021;142:689\u2013706.","journal-title":"Acta Neuropathol"},{"key":"6209_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","volume":"12","author":"T Annus","year":"2016","unstructured":"Annus T, Wilson LR, Hong YT, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12:538\u201345.","journal-title":"Alzheimers Dement"},{"key":"6209_CR27","doi-asserted-by":"crossref","unstructured":"Rosenstiel P von, Gheuens S, Chen T, et al. Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer\u2019s disease (S2.003). Neurology. 2018;90.","DOI":"10.1093\/geroni\/igy023.494"},{"key":"6209_CR28","doi-asserted-by":"publisher","first-page":"e12112","DOI":"10.1002\/trc2.12112","volume":"7","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7:e12112.","journal-title":"Alzheimers Dement (N Y)"},{"key":"6209_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/cpt.2535","volume":"111","author":"S Retout","year":"2022","unstructured":"Retout S, Gieschke R, Serafin D, Weber C, Frey N, Hofmann C. Disease modeling and model-based meta-analyses to define a new direction for a phase III program of gantenerumab in Alzheimer\u2019s disease. Clin Pharmacol Ther. 2022;111:857\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"6209_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350.","journal-title":"Nat Rev Neurol"},{"key":"6209_CR31","doi-asserted-by":"publisher","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","volume":"5","author":"R Potter","year":"2013","unstructured":"Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-\u03b242 production, exchange, and irreversible loss in presenilin mutations carriers. Sci Transl Med. 2013;5:189ra77. https:\/\/doi.org\/10.1126\/scitranslmed.3005615.","journal-title":"Sci Transl Med"},{"issue":"12","key":"6209_CR32","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/alz.12564","volume":"18","author":"J Shah","year":"2022","unstructured":"Shah J, Gao F, Li B, Ghisays V, Luo J, Chen Y, et al. Deep residual inception encoder-decoder network for amyloid PET harmonization. Alzheimers Dement. 2022;18(12):2448\u201357. https:\/\/doi.org\/10.1002\/alz.12564.","journal-title":"Alzheimers Dement."},{"key":"6209_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","volume":"19","author":"Y Su","year":"2018","unstructured":"Su Y, Flores S, Hornbeck RC, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406\u201316.","journal-title":"Neuroimage Clin"},{"key":"6209_CR34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00259-009-1129-6","volume":"36","author":"N Tolboom","year":"2009","unstructured":"Tolboom N, Yaqub M, Boellaard R, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2009;36:1629\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6209_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53:378\u201384.","journal-title":"J Nucl Med"},{"key":"6209_CR36","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimer\u2019s Dement. 2013;9:S72\u201383.","journal-title":"Alzheimer\u2019s Dement"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06209-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:03:15Z","timestamp":1729191795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6209"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06209-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"8 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (version 7) and the International Conference on Harmonization and Good Clinical Practice guidelines. Protocols for the study have received prior approval by the local Institutional Review Board (IRB) or Ethics Committee of each DIAN site and by the Washington University IRB for the Knight ADRC. The clinical trial registration number is NCT01760005.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participants or their caregivers provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This manuscript does not contain the details, images, or video of any individual person.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Dr. Klunk is a co-inventor of <sup>11<\/sup>C-PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Dr. Roberson has been on a DSMB for Lilly and a SAB for AGTC and has received licensing fees from Genentech and owns intellectual property related to tau. Dr. Holtzman, currently Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Associate Director of the Knight ADRC where the research is being conducted, is an inventor on patients for solanezumab, currently being tested in the DIAN-TU clinical trials. If solanezumab is approved as a treatment for Alzheimer\u2019s disease or Dominantly Inherited Alzheimer\u2019s Disease, Washington University and Dr. Holtzman will receive part of the net sales of solanezumab from Eli Lilly, which has licensed patents related to solanezumab from Washington University.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}